• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA approves Boston Scientific’s Synergy absorbable stent

FDA approves Boston Scientific’s Synergy absorbable stent

October 5, 2015 By Brad Perriello

Boston Scientific's Synergy bioabsorbable stentUPDATED Oct. 14, 2015, with comment from Boston Scientific’s Dr. Craig Thompson.

The FDA approved Boston Scientific‘s (NYSE:BSX) Synergy drug-eluting stent for treating coronary artery disease, sending BSX shares up today and making BSX the 1st U.S. entrant on the next front in the stent wars.

The Marlborough, Mass.-based company said the Synergy device’s bioabsorbable polymer is designed to dissolve completely after delivering its payload of the anti-restenosis drug everolimus, leaving behind a bare-metal stent. Synergy elutes the drug for about 3 months and the polymer coating is absorbed “shortly” thereafter, Boston Scientific said.

The news pushed BSX shares up 2.8% to $17.40 apiece today in pre-market trading, before their $17.36 opening this morning. The company said it’s asked the FDA for an investigational device exemption for a new, 3-month study evaluating Synergy in conjunction with a short course of dual anti-platelet therapy and expects to launch the trial, Evolve DAPT, during the 1st quarter next year.

“The introduction of the first bioabsorbable polymer stent in the U.S. is a tremendous milestone in the evolution of stent technology,” interventional cardiology president Kevin Ballinger said in prepared remarks. “The Synergy stent is a next generation therapy designed to improve patient outcomes and ultimately reduce health care costs associated with the treatment of coronary artery disease.”

“Data from the Evolve II trial, which included the most complex patient population studied in a U.S. regulatory approval stent trial, demonstrated exceptional performance and safety of the Synergy stent,” added Evolve II principal investigator Dr. Dean Kereiakes of Cincinatti’s Christ Hospital Heart & Vascular Center. “The U.S. cardiology community will have access to a bioabsorbable polymer DES which will provide excellent clinical outcomes and should optimize vessel healing.”

Dr. Craig Thompson, senior vice president & chief medical officer for Boston Scientific’s interventional cardiology division, told MassDevice.com that Synergy is expressly designed to promote healing in the arterial wall.

“The concept and goal is to reduce the adverse events that are caused by long-term polymer exposure to the artery,” Thompson told us from the annual Transcatheter Cardiovascular Therapeutics conference in San Francisco. “I think there were 2 fundamental unmet needs. One is that physicians and patients are tethered to this dual antiplatelet therapy to protect the stent. We know that Synergy heals differentially and we believe it’s going to lend itself to having lower thrombotic events, in what we have seen thus far in the data that’s available.

“Second is that permanent-polymer drug-eluting stents, the current generation, while an improvement on the 1st generation, we still see a loss of efficacy, safety and efficacy, of about 2% per year, every year after the first year. The results don’t stand up as well over time,” he said. “We believe that this is from chronic inflammation in the artery and neoatherosclerosis, and by reducing that inflammation we’ll improve outcomes with this product.”

Filed Under: Cardiovascular, Food & Drug Administration (FDA), Stents Tagged With: Bioabsorbable Stents, Boston Scientific

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy